GENE ONLINE|News &
Opinion
Blog

COVID-19 Treatment
EMA Begins Reviewing Cancer Medicine for COVID-19 Without Manufacturer’s Application
2022-07-28
Monoclonal Antibody Discovered to Potentially Act Against All Coronaviruses
2022-07-25
Brii Biosciences Begins Marketing COVID-19 Antibody Cocktail Therapy in China
2022-07-07
Genetics May Be a Factor in Varying COVID-19 Severity
2022-05-20
FDA Rejects Emergency Use Authorization for Common and Inexpensive Antidepressant COVID-19 Treatment
2022-05-20
Pfizer to Address COVID-19 Reinfection After Paxlovid Treatment
2022-05-19
Kintor Pharma’s Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
2022-04-05
Can Vaccination Provide Protection Against Highly Infectious BA.2 Omicron Variant?
2022-03-23
Shionogi’s COVID-19 Oral Drug and Nasal Vaccine Makes Headway in Trials
2021-09-29
Purine Repressing Probiotic Might Halt COVID-19, says Korean Researchers
2020-03-21
Weekly Cover: Taiwan Synthesizes Potential COVID-19 Treatment Favilavir
2020-03-04
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!